Genetic and Inflammatory PolyneuropathiesPOLYFRANCT07851844
Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France
An observational study of Genetic and Inflammatory Polyneuropathies, run by Assistance Publique - Hôpitaux de Paris at 26 sites in France.
Trial summary
To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Genetic and Inflammatory Polyneuropathies
- How many people
- 1,000 participants
- Where
- 26 sitesFrance
- Study dates
- 1 Nov 2026to 1 Nov 2036
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults diagnosed with genetic or inflammatory polyneuropathy and followed in participating neurology centers in France.
Who may be able to join
- Adult patients aged 18 years or older.
- Patients with a diagnosis of genetic or inflammatory polyneuropathy, confirmed by complementary examinations performed as part of routine care, including genetic, biological and/or electrophysiological tests.
Who cannot join
- Patient opposition to the use of their routine care data for research purposes.
Trial locations and contacts
26 sites in 1 country. Contact the study team or a site near you to ask about taking part.
26 sites in 1 country
France26 sites
CHU Amiens-Picardie - Site Sud
Amiens
Philippe-Edouard MERLE, merle.philippe@chu-amiens.fr
CHU Angers
Angers
Julien CASSEREAU, JuCassereau@chu-angers.fr
Hôpital Pellegrin, CHU Bordeaux
Bordeaux
Guilhem SOLE
Hôpital Morvan, CHU Brest
Brest
Steeve GENESTET, steeve.genestet@chu-brest.fr
Hôpital Pierre Wertheimer, HCL
Bron
Juliette SVAHN, juliette.svahn@chu-lyon.fr
Hôpital Gabriel-Montpied, CHU Clermont-Ferrand
Clermont-Ferrand
Frédéric TAITHE, ftaithe@chu-clermontferrand.fr
Hôpital François Mitterrand, CHU Dijon
Dijon
Agnès JACQUIN-PIQUES, agnes.jacquin-piques@chu-dijon.fr
Centre Hospitalier Annecy Genevois
Épagny
Océane BOUCHOT, obouchot@ch-annecygenevois.fr
Hôpital Raymond-Poincaré
Garches
Edouard BERLING, edouard.berling@aphp.fr
CHU Grenoble - Site Sud
Grenoble
Emmeline LAGRANGE, ELagrange@chu-grenoble.fr
CHU de la Réunion - GH Sud Réunion - Saint-Pierre
La Réunion
Ariane CHOUMERT, ariane.choumert@chu-reunion.fr
Hôpital Bicêtre
Le Kremlin-Bicêtre
Andoni ECHANI-LAGUNA, andoni.echaniz-laguna@aphp.fr
Hôpital Salengro, CHU de Lille
Lille
Céline TARD, celine.tard@chu-lille.fr
Hôpital Dupuytren, CHU Limoges
Limoges
Laurent MAGY, laurent.magy@chu-limoges.fr
Hôpital de la Timone, AP-HM
Marseille
Shahram ATTARIAN, shahram.attarian@ap-hm.fr
F-Esselin@Chu-Montpellier.Fr
Montpellier
Florence ESSELIN, f-esselin@chu-montpellier.fr
CHU Nantes - Hôtel-Dieu - Hôpital Mère-Enfant
Nantes
Yann PEREON, Yann.Pereon@univ-nantes.fr
Hôpital Pasteur, CHU Nice
Nice
Sabrina SACCONI, SACCONI.S@chu-nice.fr
Hôpital Universitaire Carémeau, CHU Nîmes
Nîmes
Ioana Maria ION
Hôpital Ambroise Paré
Paris
Pierre LOZERON, pierre.lozeron@aphp.fr
Hôpital La Pitié-Salpetrière
Paris
Tanya STOJKOVIC, tanya.stojkovic@aphp.fr
Hôpital Maison Blanche, CHU Reims
Reims
Maxime KIRCHHOFER, mkirchhofer@chu-reims.fr
Hôpital Charles-Nicolle, CHU Rouen
Rouen
Anne-Laure BEDAT-MILLET, anne-laure.millet@chu-rouen.fr
Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg
Strasbourg
Jean-Baptiste CHANSON, jean-baptiste.chanson@chru-strasbourg.fr
Hôpital Rangueil, CHU Toulouse
Toulouse
Pascal CINTAS, cintas.p@chu-toulouse.fr
Hôpital Bretonneau CHRU de Tours
Tours
Stéphane BELTRAN, s.beltran@chu-tours.fr
About this study
To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France.
Read the detailed description
To describe the clinical, electrophysiological, and genetic characteristics of genetic and inflammatory peripheral neuropathies in detail in order to advance our understanding of these rare and disabling diseases. This detailed description is also necessary with a view to the future use of innovative treatments. In recent years, there have indeed been spectacular advances in the field of genetic therapies (siRNA, antisense oligonucleotides, gene therapy) and next-generation immunosuppressive therapies (complement inhibitors, anti-FcRN), all of which are applicable in the short- to medium-term for genetic and inflammatory polyneuropathies.
This is a multicenter, prospective-retrospective study using data collected as part of routine clinical care.The objectives are as follows:
- Describe the different subtypes of genetic and inflammatory pyneuropathies in France
- Describe the demographic characteristics
- Describe the geographic distribution
- Describe the electrophysiological findings
- Describe the genetic abnormalities
- Keywords
- Rare Diseases, Genetic Testing, Electrophysiology, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Charcot-Marie-Tooth Disease, Inflammatory Neuropathy, Hereditary Neuropathy, Polyneuropathy
- Medical subject headings
- Neuritis, Rare Diseases, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Charcot-Marie-Tooth Disease, Polyneuropathies
What is being measured
The primary outcome is the main question the study is designed to answer.
Number and percentage of participants by type of polyneuropathy
Participants will be classified as having genetic or inflammatory polyneuropathy according to the diagnosis documented in their medical records. The number and percentage of participants in each category will be reported.
Measured: At inclusion, based on the diagnosis documented in the medical record.
Secondary outcomes (5)
Number and percentage of participants by polyneuropathy subtype
The number and percentage of participants in each genetic or inflammatory polyneuropathy subtype, as documented in the medical records, will be reported.
Measured: At inclusion, based on the diagnosis documented in the medical record.
Demographic characteristics of patients
Description of demographic characteristics of patients with genetic or inflammatory polyneuropathies, including age, sex and other available demographic data.
Measured: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.
Geographical distribution of patients
Description of the geographical distribution of patients with genetic or inflammatory polyneuropathies included in participating centers in France.
Measured: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.
Number and percentage of participants by electrophysiological neuropathy pattern
The electrophysiological neuropathy pattern documented in the medical record will be classified as axonal, demyelinating or mixed. The number and percentage of participants in each category will be reported.
Measured: At inclusion, based on electrophysiological examinations available in the medical record.
Genetic abnormalities
Description of genetic abnormalities identified in patients with genetic or inflammatory polyneuropathies, when genetic analysis results are available in the medical records.
Measured: At baseline, corresponding to the date of inclusion in the study, using genetic data available in the medical record up to that date.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Nov 2036 (estimated)
- Study completion1 Nov 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genetic and Inflammatory PolyneuropathiesStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07851844
- Sponsor's protocol ID
- APHP260582
- Acronym
- POLYFRA
- Status last verified
- Jun 2026
- First submitted
- 22 Jun 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No